Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
(Values in U.S. thousands)
| 04-2026 | 01-2026 | 10-2025 | 07-2025 | 04-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,979 | -29,752 | -117,302 | -79,422 | -50,431 |
| Depreciation Amortization | -716 | -402 | -2,558 | -2,307 | -1,769 |
| Accounts payable and accrued liabilities | -4,895 | -4,270 | 4,942 | 970 | 152 |
| Other Working Capital | -7,137 | -2,538 | 9,740 | -386 | -1,452 |
| Other Operating Activity | 13,326 | 8,059 | 5,939 | 6,868 | 4,857 |
| Operating Cash Flow | $-59,401 | $-28,903 | $-99,239 | $-74,277 | $-48,643 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -102,408 | -126,144 | -23,653 | -64,590 | -66,673 |
| PPE Investments | -251 | -153 | -1,485 | -1,048 | -344 |
| Investing Cash Flow | $-102,659 | $-126,297 | $-25,138 | $-65,638 | $-67,017 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 25,000 | 25,000 | N/A | N/A | N/A |
| Debt Repayment | -23,053 | -23,053 | -699 | -699 | N/A |
| Common Stock Issued | 149,780 | 149,776 | 2,223 | 232 | 200 |
| Other Financing Activity | -9,993 | -10,063 | 0 | 0 | 0 |
| Financing Cash Flow | $141,734 | $141,660 | $1,524 | $-467 | $200 |
| Exchange Rate Effect | 1 | 1 | 1 | 1 | 1 |
| Beginning Cash Position | 50,152 | 50,152 | 173,004 | 173,004 | 173,004 |
| End Cash Position | 29,827 | 36,613 | 50,152 | 32,623 | 57,545 |
| Net Cash Flow | $-20,325 | $-13,539 | $-122,852 | $-140,381 | $-115,459 |
| Free Cash Flow | |||||
| Operating Cash Flow | -59,401 | -28,903 | -99,239 | -74,277 | -48,643 |
| Capital Expenditure | -251 | -153 | -1,485 | -1,048 | -344 |
| Free Cash Flow | -59,652 | -29,056 | -100,724 | -75,325 | -48,987 |